DEFINITIVE RADIOCHEMOTHERAPY IN ESOPHAGEAL CANCER – A SINGLE INSTITUTION EXPERIENCE

  • Franc Anderluh Institute of Oncology Ljubljana
  • Miha Toplak Institute of Oncology Ljubljana
  • Vaneja Velenik Institute of Oncology Ljubljana
  • Irena Oblak Institute of Oncology Ljubljana
  • Ajra Šečerov Ermenc Institute of Oncology Ljubljana
  • Ana Jeromen Peressutti Institute of Oncology Ljubljana
  • Jasna But Hadžić Institute of Oncology Ljubljana
  • Marija Skoblar Vidmar Institute of Oncology Ljubljana

Abstract

ABSTRACT

Background: The purpose of this retrospective study was to evaluate the treatment results with definitive radiochemotherapy of patients with esophageal cancer, treated in a single institution in the period from 2010 to 2017.

Patients and methods: Fifty-five patients with esophageal cancer and the mean age of 62 years (range: 29.2-80.8 years) were treated with definitive radiochemotherapy with curative intent. Majority of patients had squamous cell cancer (53 patients - 96.4%) in the stage T3 or T4 (47 patients - 85.5%) and/or N+ (35 patients - 63.6%).  All patients were irradiated to a total dose to the tumor of 70 Gy (1.8-2 Gy per fraction) in upper third (cervical) tumors or to the mean total dose of 57.6 Gy (1.8 Gy per fraction) in middle third (intrathoracic) tumors. All but one patient received concomitant chemotherapy, with majority of them (41 patients – 74.5%) receiving concomitant chemotherapy with 5-fluorouracil in continuous 96 hours infusion and cisplatin.

Results: Median follow-up time for the whole group of patients was 16.8 months (range: 0.3-81.8 months). At the time of analysis 14 (25.5%) patients were still alive. Rates for overall survival, locoregional control and disease-free survival at two and five years were as follows: 47% and 19.4%, 43.7% and 41%, 32.1% and 11.5%, respectively. None of the analyzed factors had a statistically significant impact on survival in univariate analysis. 

Conclusions: Our results of treatment with definitive radiochemotherapy in patients with esophageal cancer are similar to the results of other studies. Majority of patients ended the treatment according to the protocol, which at least in part can be attributed to the adequate and well organized supportive treatment in our institution.

Author Biographies

Franc Anderluh, Institute of Oncology Ljubljana
Department of Radiotherapy
Miha Toplak, Institute of Oncology Ljubljana
Department of Radiotherapy
Vaneja Velenik, Institute of Oncology Ljubljana
Department of Radiotherapy
Irena Oblak, Institute of Oncology Ljubljana
Department of Radiotherapy
Ajra Šečerov Ermenc, Institute of Oncology Ljubljana
Department of Radiotherapy
Ana Jeromen Peressutti, Institute of Oncology Ljubljana
Department of Radiotherapy
Jasna But Hadžić, Institute of Oncology Ljubljana
Department of Radiotherapy
Marija Skoblar Vidmar, Institute of Oncology Ljubljana
Department of Radiotherapy
Published
2019-12-03
How to Cite
Anderluh, F., Toplak, M., Velenik, V., Oblak, I., Šečerov Ermenc, A., Jeromen Peressutti, A., But Hadžić, J., & Skoblar Vidmar, M. (2019). DEFINITIVE RADIOCHEMOTHERAPY IN ESOPHAGEAL CANCER – A SINGLE INSTITUTION EXPERIENCE. Radiology and Oncology, 53(4), 480-487. Retrieved from https://www.radioloncol.com/index.php/ro/article/view/3251
Section
Clinical oncology